drug_type
RELEVANT_DRUG
intervention_type
cellular gene therapy (CAR-NK)
drug_description
iPSC-derived natural killer cells engineered with dual chimeric antigen receptors targeting CD33 and CLL1 (CLEC12A) to recognize AML blasts and mediate NK cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Killer Cells, Natural
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
iPSC-derived natural killer cells engineered with dual chimeric antigen receptors against CD33 and CLL1 (CLEC12A) bind these antigens on AML blasts, triggering NK-cell activation and targeted cytotoxicity (perforin/granzyme release and cytokine-mediated killing) to eliminate leukemia cells and reduce antigen escape.
drug_name
CD33/CLL1 dual CAR-NK cells
nct_id_drug_ref
NCT05987696